DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02920190

WithdrawnPhase 4

Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat

Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA)

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

0

Recruiting sites

—

Enrollment

—

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥27

Primary endpoint

•Epicardial Fat Thickness

Identifiers

Registered as

NCT IDNCT02920190
Org study ID20160568

Timeline

Milestones

Study first posted2016-09-30estimated
Study start2020-09-01estimated
Last update posted2020-09-21actual
Primary completion2021-09-01estimated
Study completion2021-12-31estimated

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•BMI ≥27 kg/m2
•At least one overweight/obesity related comorbidity (such as type 2 diabetes, pre-diabetes [IFG, IGT], hypertension, dyslipidemia)
•Age > 18 and < 70 years old

Exclusion criteria

•Known contra-indications to Liraglutide, such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of MEN, in accordance with risks and safety information included in the latest updated Prescribing Information for Victoza®
•Type 1 diabetes, as defined by American Diabetes Association (ADA) criteria
•Insulin dependent or treated type 2 diabetes
•Current use of other injectable incretins
•History of diabetes ketoacidosis
•Advanced Chronic Kidney Disease, as defined by Glomerular Filtration Rate (GFR) < 30 mL/min/1.73m2
•Clinical signs or symptoms of New York Heart Association (NYHA) class III-IV heart failure
•Clinical or laboratory evidences of chronic active liver diseases
•Acute or chronic infective diseases
•Known or suspected allergy to Liraglutide, excipients, or related products
•Pregnant, breast-feeding or the intention of becoming pregnant
•Females of childbearing potential who are not using adequate contraceptive methods

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Safety / tolerability / PK
1
Other (unclassified)
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

Change in Epicardial Fat Thickness

Time frame:Baseline, 12 months

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Change in serum immunoglobulins

Time frame:Baseline, 12 months

change from baseline, descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Change in plasma ceramide levels

Time frame:Baseline, 12 months

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.